2014年 IAAO

国際フォーラム2014(IAAO2014)

Theme:Convergence for Breakthroughs in Oncology Therapy

Opening Remarks

OpeningRemarks Osamu Nagayama, Chairman
Chugai Academy for Advanced Oncology

1. Individualized Cancer Therapy

▶ Functionalizing Data from the Cancer Genome – the Case of RAF Mutations

Neal Rosen
Speaker:
Neal Rosen, MD, PhD
Memorial Sloan-Kettering Cancer Center, USA
Chair:
Kiyohiko Hatake, MD, PhD
Cancer Institute Hospital, Japan
Kiyohiko Hatake

▶ Maximizing Responses to Radioiodine in Thyroid Cancer by Sustained MAPK Pathway Inhibition

James A. Fagin
Speaker:
James A. Fagin, MD
Memorial Sloan-Kettering Cancer Center, USA
Chair:
Yuko Kitagawa, MD, PhD
Keio University, Japan
Yuko Kitagawa

▶ Challenges and Opportunities Facing Tumor and Therapeutics Heterogeneity of Kidney Cancer

James J. Hsieh
Speaker:
James J. Hsieh, MD, PhD
Memorial Sloan-Kettering Cancer Center, USA
Chair:
Chikashi Ishioka, MD
Tohoku University, Japan
Chikashi Ishioka

▶ Molecular Pathology: Detection of Gene Fusions in Cancer

Anthony J. Iafrate
Speaker:
Anthony J. Iafrate, MD, PhD
Harvard Medical School, USA
Chair:
Makoto Ogawa, MD
Aichi Cancer Center, Japan
Makoto Ogawa

2. Towards a More Productive Relationship Between Academia and Industry

▶ The European Cancer Patient Bill of Rights: A Catalyst for Change

Patrick G. Johnston
Speaker:
Patrick G. Johnston, MD, PhD
The Queen’s University Belfast, UK
Chair:
Yasuhiro Fujiwara, MD, PhD
National Cancer Center, Japan
Yasuhiro Fujiwara

▶ Academic-Industry Collaboration Drives Cancer Drug Development

Bruce A. Chabner
Speaker:
Bruce A. Chabner, MD
Harvard Medical School, USA
Chair:
Nagahiro Saijo, MD, PhD
Japanese Society of Medical Oncology, Japan
Nagahiro Saijo

▶ Industry-Academia Relationship after Diovan Scandal in Japan

Yasuhiro Fujiwara
Speaker:
Yasuhiro Fujiwara, MD, PhD
National Cancer Center, Japan
Chair:
Bruce A. Chabner, MD
Harvard Medical School, USA
Bruce A. Chabner

▶ Panel Discussion

Panel Discussion

3. Physiological Versatility of Cancer

▶ Defining the Underlying Principles of Resistance to Targeted Cancer Therapeutics

Levi A. Garraway
Speaker:
Levi A. Garraway, MD, PhD
Harvard Medical School, USA
Chair:
Hiroyuki Mano, MD, PhD
The University of Tokyo, Japan
Hiroyuki Mano

▶ Pharmacology, Feedback, and Novel Agents in the MAP Kinase Pathway

Keith T. Flaherty, MD
Speaker:
Keith T. Flaherty, MD
Harvard Medical School, USA
Chair:
Chikashi Ishioka, MD
Tohoku University, Japan
Chikashi Ishioka, MD

▶ Beyond Oncogenes: What Will Be the Next Generations of Anticancer Targets?

Tak W. Mak, OC, PhD, DSc, FRSC, FRS
Speaker:
Tak W. Mak, OC, PhD, DSc, FRSC, FRS
Research at University Health Network, Canada
Chair:
Kohei Miyazono, MD, PhD
The University of Tokyo, Japan
Kohei Miyazono, MD, PhD

4. Immunology in Cancer Treatment

▶ Translating Cancer Immunoediting Principles to Cancer Immunotherapy

Robert D. Schreiber, PhD
Speaker:
Robert D. Schreiber, PhD
Washington University, USA
Chair:
Mitsuaki Yoshida, PhD
Japanese Foundation For Cancer Research, Japan
MitsuakiYoshida

▶ Control of Tumor Immunity by Regulatory T Cells

Shimon Sakaguchi, MD, PhD
Speaker:
Shimon Sakaguchi, MD, PhD
Osaka University, Japan
Chair:
Ryuzo Ueda, MD, PhD
Aichi Medical University, Japan
Ryuzo Ueda, MD, PhD.

▶ Tumor Site Immune Modulation Therapy

Lieping Chen, MD, PhD
Speaker:
Lieping Chen, MD, PhD
Yale University, USA
Chair:
Hirotoshi Akita, MD, PhD
Hokkaido University, Japan
Hirotoshi Akita, MD, PhD
一般社団法人 中外Oncology学術振興会議